SGLT2 Inhibitors and CV Outcomes

Introduction to SGLT2 Inhibitors

EMPA-REG OUTCOME and CANVAS CVOTs

EMPA-REG OUTCOME Trial Design

CANVAS and CANVAS-R Trial Design

EMPA-REG OUTCOME and CANVAS Demographics

Heart Failure and Diabetes

EMPA-REG OUTCOME and CANVAS Results

DECLARE-TIMI58 and VERTIS-CV Demographics

DECLARE-TIMI58 and VERTIS-CV Outcome Measures

CANVAS Analysis of 2 Subgroups

EMPA-REG OUTCOME, CANVAS, DECLARE-TIMI58 , VERTIS-CV

Interpreting CVOT Data Into Clinical Practice

EMPA-REG OUTCOME and CANVAS Safety

EMPA-REG OUTCOME and CANVAS Lower Limb Amputations

CANVAS Subanalysis Heart Failure

EMPA-REG OUTCOME Subanalysis Peripheral Artery Disease

Clinical Application

When to Start an SGLT2 Inhibitor?

Concluding Remarks

Abbreviations